Bevacizumab and erlotinib in EGFR wild type NSCLC patients

Author Phase Line of treatment Pts Treatment Response rate(%) Progression-free survival (months) Overall survival (months)
Herbst et al. [17] I/II Second line 40 Erlotinib + Bevacizumab 20 95% CI: 7.6-32.4% 7.0; 1-year PFS = 38.0%, 95% CI: 24.3-59.6% 12.6; 1-year OS = 54.2%,
95% CI: 40.0%-73.4%
Herbst et al. [18] II Second line 120 Bevacizumab + CT* vs. bevacizumab + erlotinib vs. CT* 12.5 vs. 17.9 vs. 12.2 4.8 vs. 4.4 vs. 3.0 HR: 0.66, 95% CI: 0.38-1.16 HR: 0.72, 95% CI: 0.42-1.23 12.6 vs. 13.7 vs. 8.6 HR: 0.71,
95% CI: 0.41-1.21 HR: 0.78,
95% CI: 0.46-1.31
Herbst et al. BeTa trial [19] III Second line 636 Erlotinib + Bevacizumab vs. Erlotinib + placebo 14 vs. 7 3.4 vs.1.7 HR: 0.62, 95% CI: 0.52-0.75 9.3 vs. 9.2 HR: 0.97, 95% CI: 0.80-1.18, P = 0.7583
Wang et al. [20] III Second line 297 Erlotinib + Bevacizumab + Panitumumab vs. Erlotinib + placebo 38 vs.15 P = 0.014 4.6 vs. 1.9 P = 0.003 10.4 vs. 8.9 P = 0.031
Besse et al. BRAIN trial [21] II Second line 24 Erlotinib + Bevacizumab 12.5 95% CI: 2.7-32.4 6.3 95% CI: 3.0-8.4 12.0 95% CI: 8.9-20.2
Johnson et al. ATLAS trial [22] III Maintenance after I line 745 Erlotinib + Bevacizumab vs. Bevacizumab alone - 4.8 vs. 3.7, HR: 0.71, 95% CI: 0.58-0.86 P < 0.001 14.4 vs. 13.3 HR: 0.92, 95% CI: 0.7-1.21 P = 0.5341
Dingemans et al. [23] II First line 47 Erlotinib + Bevacizumab 25 3.8 (95% CI: 2.3-5.4) 6.9 (95% CI: I 5.5-8.4)
Zappa et al. trial SAKK 19/05 [24] II First line 101 Erlotinib + Bevacizumab 17.8 4.1 (95% CI: 2.9-5.5) 14.1 (95% CI: 10.7-19.0)
Ciuleanu et al. TASK trial [25] II First line 200 Erlotinib + Bevacizumab vs. Chemo + Bevacizumab 23.8 vs. 34.4, P = 0.19 18.4 vs. 25 weeks HR 2.05, 95% CI: 1.11-3.77 16.4 vs. n.r HR:1.24, 95% CI: 0.75-2.05
Thomas et al. INNOVATIONS [26] II First line 224 Erlotinib + Bevacizumab vs. Cisplatin + Gemcitabine + Bevacizumab 12 vs. 36, P < 0.0001 3.5 vs. 6.9 HR: 1.85; 95% CI:1.39-2.45 P < 0.0001 12.6 vs.17.8 HR: 1.41; 95% CI: 1.01-1.97 P = 0.04

Docetaxel or erlotinib; n.r: not reached